Document Detail


VEGF and bFGF increase survival of xenografted human ovarian tissue in an experimental rabbit model.
MedLine Citation:
PMID:  24062194     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The aim of this study is to determine whether vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) could increase the survival of xenografted human ovarian tissue in an experimental rabbit model.
METHODS: Fresh human ovarian tissue was xenotransplanted into the back muscle of 25 castrated female New Zealand rabbits for 6 weeks with the immunosuppression of FTY720 (2 mg/kg/d). Rabbits were randomly divided into five experimental groups: (A) graft and host treatment with VEGF (50 ng/ml); (B) graft and host treatment with bFGF (100 ng/ml); (C) graft and host treatment with VEGF(50 ng/ml) + bFGF (100 ng/ml); (D) graft and host treatment with normal saline; (E) control group, no treatment. 4 weeks after transplantation, human menopausal gonadotropin (HMG) 10 IU was administered every second day in group A, group B, group C and group D for 2 weeks. Graft survival was assessed by graft recovery rate, histological analysis, immunohistochemical staining for CD31 and Ki-67expression, TUNEL assay.
RESULTS: After 6 weeks of grafting, the number of CD31-positive stained cells increased significantly in group A, group B and group C compared to the control group. All groups showed strong Ki-67 immunostaining in ovarian stroma. Only one rabbit in group C retained the grafts' follicles. Grafting resulted in relative lower fibrosis in group A and group C compared to the control group. Apoptosis was significantly lower in group C compared to the control group.
CONCLUSIONS: Fresh human ovarian cortex grafted into the back muscle of rabbit can sustain part of ovarian tissue function with the immunosuppression of FTY720, although follicle number diminishes significantly after grafting. The administration of VEGF and bFGF, especially the combination of them, may trigger angiogenesis, reduce apoptosis and fibrosis, increase survival in transplanted human ovarian tissue.
Authors:
Lin Wang; Ying-fen Ying; Yin-luan Ouyang; Jing-fen Wang; Jian Xu
Related Documents :
23949024 - Effects of proximal and distal robot-assisted upper limb rehabilitation on chronic stro...
23729054 - North cork hse orthodontic treatment waiting list 2009-2010: retrospective audit of pat...
24322034 - A histological analysis of gingival condition associated with orthodontic treatment.
24459204 - Treatment of naviculo-first cuneiform coalition of the foot.
24364174 - Comparison of amnion allograft with connective tissue graft for root coverage procedure...
23922184 - Combined treatment for facial rejuvenation using an optimized pulsed light source follo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-09-06
Journal Detail:
Title:  Journal of assisted reproduction and genetics     Volume:  30     ISSN:  1573-7330     ISO Abbreviation:  J. Assist. Reprod. Genet.     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-11-07     Completed Date:  2014-07-14     Revised Date:  2014-10-09    
Medline Journal Info:
Nlm Unique ID:  9206495     Medline TA:  J Assist Reprod Genet     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1301-11     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Animals
Antigens, CD31 / analysis
Apoptosis / drug effects
Cell Survival / drug effects
Female
Fibroblast Growth Factor 2 / pharmacology*
Graft Survival / drug effects*
Humans
Immunosuppressive Agents / administration & dosage
Ki-67 Antigen / analysis
Neovascularization, Physiologic / drug effects
Ovarian Follicle / transplantation*
Propylene Glycols / administration & dosage
Rabbits
Sphingosine / administration & dosage,  analogs & derivatives
Transplantation, Heterologous
Vascular Endothelial Growth Factor A / pharmacology*
Chemical
Reg. No./Substance:
0/Antigens, CD31; 0/Immunosuppressive Agents; 0/Ki-67 Antigen; 0/Propylene Glycols; 0/Vascular Endothelial Growth Factor A; 103107-01-3/Fibroblast Growth Factor 2; 3QN8BYN5QF/fingolimod; NGZ37HRE42/Sphingosine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antip...
Next Document:  Live birth following serial vitrification of embryos and PGD for fragile X syndrome in a patient wit...